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Summary Objective: To determine the clinical and microbiologic characteristics of
pneumococcal bacteremia at Sanatorio Mitre, Buenos Aires, Argentina.
Methods:One-hundred-and-seven episodes of pneumococcal bacteremia were pros-
pectively analyzed from 1993 to 1998. Demographics, clinical and microbiological
variables were studied.
Results: Eighty-one patients (76%) were adults and 26 children (24%). Most cases
(98%) were acquired in the community. Seventy-nine patients (74%) had at least
one underlying condition. The primary source of bacteremia was found in 91 pa-
tients (85%), the lungs being the most common source. Streptococcus pneumoniae
was isolated from one sterile site other than the primary focus in 25 patients (23%).
Eighty-ﬁve (79%) of the Streptococcus pneumoniae were susceptible to penicillin and
22 (21%) showed intermediate or high resistance to penicillin and 2% were additionally
resistant to ceftriaxone.
Initial antimicrobial therapy was appropriate in 95% of the cases. The overall mor-
tality was 21%, however adults admitted to the intensive care unit (ICU) had higher
mortality (81%). No patients under 14 years old died. Multivariate analysis showed
that age and recovery of the organisms from a sterile site other than the primary
focus were statistically signiﬁcant predictors of mortality.
Conclusion: Bacteremic pneumococcal infections continue to be an important world-
wide problem causing morbidity and high mortality despite supportive care and ap-
propriate antimicrobial therapy.
© 2003 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases.
Introduction
Streptococcus pneumoniae is one of the most im-
portant bacterial species pathogenic to humans.1 It
colonizes the naso-pharyngeal region from where it
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may invade both upper and lower respiratory tracts,
and reach the bloodstream. Despite the availability
of effective antibiotic therapy and vaccine, disease
caused by this organism continues to be a major
cause of morbidity and mortality worldwide.2,3
Penicillin resistant S. pneumoniae (PRSP) strains
were ﬁrst identiﬁed in Papua New Guinea in 1967.
Since the ﬁrst isolate resistant to penicillin was
reported this problem has spread throughout the
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world over the last 15 years.4—7 During this period
the frequency of PRSP isolates has rapidly increased
from 20% to 70%.6—10
Several publications have described the epidemi-
ology, serotype proﬁle, penicillin resistance and
therapy of pneumococcal infections in Latin Amer-
ica; however, the clinical aspects of bacteremia
due to strains of S. pneumoniae have not been
appropriately investigated in this region.11—15
The purpose of the present study is to describe
the clinical and microbiological characteristics of
pneumococcal bacteremia in a single center in
Buenos Aires, Argentina.
Methods
Setting
This study was performed at Sanatorio Mitre,
Buenos Aires, Argentina, a 360-bed tertiary pri-
vate care center. The ICU has 26 beds and included
medical and surgical patients.
Study design and data collection
Between January 1993 to June 1998, 107 cases of
pneumococcal bacteremia occurring in 107 inpa-
tients were studied. Analyzed variables included:
age, sex, underlying medical conditions, site of pri-
mary infection, isolation of S. pneumoniae from
sterile sites other than the primary focus, require-
ment of hospitalization in ICU on admission, pre-
vious use of -lactam antibiotics during the last
month, susceptibility of organism to penicillin and
ceftriaxone, and mortality. Information collected
on potential risk factors for invasive pneumococ-
cal disease included a history of tobacco smoking,
malignancy, cardiac disease, diabetes mellitus, and
HIV infection.
Deﬁnitions
Pneumococcal bacteremia was deﬁned as isolation
of S. pneumoniae in at least one blood culture.
Pneumonia was deﬁned if a patient was found to
have signs and symptoms of infection in the lower
respiratory tract and pulmonary inﬁltrate on chest
X-ray. Primary bacteremia was considered when
no focus of infection was identiﬁed by routine
methods.
Patients ≥ 14 years old were considered adults.
For the purpose of risk factors analysis, age was
categorized in the following groups: <14; ≥14 <65
and ≥65 years old.
S. pneumoniae was identiﬁed on the basis of
typical colonial morphology on sheep blood agar,
Gram staining, optochin disk diffusion and bile
solubility, and latex agglutination tests. Antibiotic
susceptibility was tested by the disk diffusion tech-
nique on Mueller-Hinton agar supplemented with
5% sheep blood. Minimal inhibitory concentration
(MIC) was determined by the macrodilution method
using cation-adjusted Mueller-Hinton broth with
5% lysed horse blood and interpreted according to
the standards of the National Committee for Clin-
ical Laboratory Standards. A 1g oxacillin disk was
used to screen for resistance to penicillin.16,17
An isolate was deﬁned as susceptible, interme-
diately resistant, and highly resistant to penicillin
when the MICs were ≤0.06g/ml; 0.12—1g/ml,
and ≥2g/ml, respectively. For ceftriaxone the
MIC breakpoints were ≤0.5g/ml, 1g/ml, and
≥2g/ml, respectively.17
The term ‘penicillin nonsusceptible’ includes
both penicillin-intermediate and penicillin-resistant
strains.
Statistical analysis
The statistical signiﬁcance of qualitative variables
was analyzed with either the 2 test or Fischer’s
exact test. Group differences were analyzed by the
Mann-Whitney test. Multivariate analyses were per-
formed by the Cox proportional hazard regression
model.
Results
During 64 months, 107 episodes of pneumococ-
cal bacteremia were identiﬁed in 107 patients.
There were 63 (59%) male and 44 (41%) female
patients. Nearly all (98%) of the episodes were of
community-acquired disease.
Eighty-one patients (76%) were adults (mean age
64 years). Twenty-six patients (24%) were children
(mean age 26 months, range 2—108 months).
Recognized predisposing conditions were present
in 79 of the patients (74%). Those younger than 14
years had predisposing diseases in only 38% of the
cases, while of those aged ≥14 and <65 years it
was 65% (p < 0.05). This is in sharp contrast to the
elderly patients (≥65 years), all of whom had one or
more predisposing diseases (Figure 1). All but one
were found to be HIV negative by the ELISA method.
A primary site of infection was found in 91 pa-
tients (85%). The lungs (73%), were the most com-
mon source of infection in all groups (Table 1).
The other sources were the peritoneum (5%) and
meninges (4%). In 16 patients (15%) the source was
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Figure 1 Predisposing disease among patients with
Pneumococcal bacteremia by age (n:107). #COPD:
Chronic Obstructive Pulmonary Disease; **CHF: Conges-
tive Heart Failure.
unknown. Pneumococci were isolated from sterile
sites other than the primary focus in 25 patients
(23%); the most frequent was empyema.
Admission to ICU was less frequent among pa-
tients younger than 14 years old than patients
older than 14 years (27 vs. 2; p < 0.01). The mean
age among the adult patients admitted to ICU
was 70.2± 18.4 years (range 36—89). Twenty-four
adults (89%) admitted to ICU had predisposing fac-
tors. The two paediatric patients admitted to ICU
due to the severity of the pneumococcal infection
had no recognizable underlying conditions.
Use of a -lactam antibiotic during the month
preceding admission was reported in 16 patients
(15%). Of those, 10 (63%) were infected by a
penicillin-resistant strain (p< 0.0005). Eighty-ﬁve
episodes (79%) of bacteremia were caused by peni-
cillin susceptible strains; 17 (16%) by intermedi-
ately penicillin-resistant pneumococci and 5 (5%)
were considered highly resistant to penicillin. Two
PRSP strains (2%) demonstrated intermediate resis-
tance to ceftriaxone.
Penicillin-resistant Streptococcus pneumoniae
(PRSP) were isolated from 7 (27%) of the 26
under-14-year-olds, and from 15 (19%) of the 81
Table 1 Primary focus of pneumococcal bacteremia and distribution according to age group.
Total (%) (N = 107) <14 year (n = 26) ≥14 <65 year (n = 35) ≥65 year (n = 46)
Unknown 16 (15) 6 5 5
Lung 78 (73) 14 26 38
Peritoneum 5(5) 1 3 1
Meningitis 4 (4) 3 - 1
Others* 4 (4) 2 1 1
* Others=Cellulitis (1); Osteomyelitis (1); Acute otitis media (2).
Table 2 Initial antimicrobial therapy.
Antibiotics Number of
patients (n = 107)
Cefalosporins 62
Ampicillin/sulbactam 38
Macrolides 16*
Ciproﬂoxacin 4
None 1
* Two patients received macrolide monotherapy;
14 patients received macrolides plus -lactams at
admission.
adults. The rates of PRSP were similar in children
and in adult groups. Initial antimicrobial therapy
was appropriate to cover the causative agent in
95% of the cases (Table 2).
Twenty-three (21%) of the patients admitted with
pneumococcal bacteremia died during their admis-
sion. All fatal cases involved only adults. The adult
patients admitted to the ICU had a high mortality
rate, 81%.
On univariate analysis, mortality was signiﬁcantly
associated with admission to ICU, old age and un-
known primary focus (Table 3). No difference in
mortality was found between patients infected with
penicillin susceptible or non-susceptible pneumo-
cocci.
Univariate analysis of mortality showed a statis-
tically signiﬁcant increase in odds ratio associated
with age (Table 4). Death occurred in 26% of pa-
tients younger than 59 years of age and 56% of pa-
tients older than 80 years of age.
Multivariate analysis showed that age (RR:1.04)
and presence of S. pneumoniae in sites other than
the primary source (RR:3.8) remained statistically
signiﬁcant predictors of mortality (Table 5).
Discussion
Our data are in agreement with previous descrip-
tions of pneumococcal bacteremia in non-AIDS
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Table 3 Risk factors for mortality in patients with pneumococcal bacteremia. Univariate analysis.
Death (n = 23) Alive (n = 84) Total p
Age (mean) 70.2 ± 18.4 year 43.2 ± 31.1 year <0.0001
Age (year)
<14 0 26 26
≥14<65 7 28 35
≥65 16 30 46 <0.0025
Sex (m/f) 12/11 51/33 63/44 NS
Underlying condition (yes/total) 19/23 60/84 79/107 NS
Primary focus
Known 16 75 91
Unknown 7 9 16 <0.041
Admission to ICU
(yes/total) 22/23 7/84 29/107 <0.0001
PRSP 5 17 22 NS
PSSP 18 67 85
Other focus (yes/total) 1/23 15/84 16/107 NS
PRSP: penicillin-resistant Streptococcus pneumoniae; PSSP: penicillin-susceptible Streptococcus pneumoniae.
Table 4 Univariate analysis of mortality according
to age. Chi2 for trends: p < 0.00045.
Age (year) Number Dead (%) Odds ratio for trends
0.1—39 33 2 (6.1) 1.00
40—59 20 4 (20.0) 3.88
60—79 38 8 (21.1) 4.13
80—95 16 9 (56.3) 19.93
patients in other areas of the world.1 The mean
age of the cases analyzed was similar to most series
consulted.18—20 Almost all the pneumococcal bac-
teremia were community acquired as traditionally
reported, however, recent descriptions of nosoco-
mial acquisition of pneumococcal infections have
been reported.20—22
Underlying medical conditions were very fre-
quent amongst the adults in this series. However,
these underlying conditions may differ according
to the population studied. In Spain, 29% of all de-
tected cases of pneumococcal bacteremia in a large
teaching institution occurred in HIV patients.23 Al-
though HIV infection has been considered a risk
factor for pneumococcal infection, only one pa-
Table 5 Multivariate analysis. Cox’s proportional hazard regression.
Variable Coef.  ± ES p RR (CI 95%)
Age 0.037 ± 0.011 <0.0005 1.04 (1.01—1.06)
Other site** 1.336 ± 0.492 <0.007 3.8 (1.45—0.93)
** S. pneumoniae isolate in other site than primary focus.
tient infected with HIV was detected in this study.
Paediatric patients had fewer underlying conditions
than the adults (38% vs 65%; p: >0.05).20
The most common site of infection identiﬁed was
the lung followed by ‘unknown focus’. This was true
in all age groups and these ﬁndings are in accor-
dance with previously published data.23
Primary bacteremia was found in 15% of cases.
These data coincide with a recent report from Is-
rael and probably reﬂect the rapid initiation of an-
tibiotics in the population.24,25
In this study it was found that pneumococcal
bacteremia caused by penicillin non-susceptible
strains was associated with prior use of -lactam
antibiotics. This is in accordance with other
research.14,24,26—28
In Argentina, the average incidence of infection
with penicillin resistant strains is between 24.4—
34% in children under 5 years of age.11,14 This
research strengthens these data and expands this
statistic to include those adults with bacteremic
disease. Pneumococci with diminished suscepti-
bility to penicillin are found worldwide.20,29—31
Isolates with high level penicillin-resistance have
been encountered in many countries and in some
represent a substantial proportion of all isolates,
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such as in Spain, South Africa and Hungary.4,9,29,30
In this series it was found that 16% were of inter-
mediate resistance, 5% of high level resistance,
and 2% were additionally resistant to ceftriaxone.
Since the advent of penicillin and other an-
tibiotics, the case-fatality rates of this disease
reported in many studies have ranged from 7 to
55%.18,19,33,34 Differences in age, place of acqui-
sition of bacteremia, underlying conditions and
admission to ICU may partly account for the dis-
crepancies in mortality.10,30—33 The result of 21% is
within the reported ranges above.
In this study it was found, as it has been pre-
viously, that there is higher mortality among pa-
tients over 80 years old.18,19,30 Admission to ICU,
reﬂecting the severity of illness and the pres-
ence of underlying conditions, was associated with
the highest mortality. Although variable accord-
ing to the population studied, this is consistent
with other reports.34,35 No-one under 14 years of
age died.
Although Turett et al. recently reported that high
level penicillin resistance was an independent pre-
dictor of mortality among patients with pneumo-
coccal bacteremia, resistance to penicillin did not
inﬂuence mortality rates in this research.14,18,24,32
Unfortunately pneumococcal serotype was not
performed in the study. However, it is consid-
ered that the adult population should beneﬁt
from the pneumococcal vaccine to prevent inva-
sive infections. In Argentina the coverage of the
hepta-valent vaccine in children is 52% while in
adults the polysaccharide vaccine accounts for at
least 90% of strains that cause invasive disease.
(Mabel Regueira, personal communication)
Bacteremic pneumococcal infections continue to
be an important worldwide problem causing mor-
bidity and mortality, despite supportive care and
appropriate antimicrobial therapy.
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